The potential role of glycogen metabolism in diffuse large B-cell lymphoma

被引:3
|
作者
Jalali, Shahrzad [1 ]
Ansell, Stephen M. [1 ]
机构
[1] Mayo Clin, Div Hematol & Internal Med, 200 First St SW, Rochester, MN 55905 USA
关键词
Glucose metabolism; glycogen metabolism; lymphoma; DLBCL; SIGNALING PATHWAY; SYNTHASE KINASE-3; DRUG-RESISTANCE; MYC; PROLIFERATION; HEXOKINASE; SURVIVAL; WARBURG; CONTRIBUTES; HOMEOSTASIS;
D O I
10.1080/10428194.2019.1702185
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Diffuse large B-cell lymphoma (DLBCL) is a common and aggressive form of non-Hodgkin lymphoma that may become refractory to available standard therapies, resulting in the need for the development of novel therapeutic targets. Increased metabolic activity of DLBCL tumor cells associated with high expression of glycolysis related proteins, such as glucose transporters and hexokinases, have already been described and indicates a pivotal role for glucose and glycogen metabolism in the malignant progression of the disease. Moreover, several enzymes involved in glycolysis and glycogen metabolism, including hexokinases and glycogen synthase kinase-3, are key molecules in mediating cell survival signaling, indicating that glucose/glycogen metabolism is tightly linked to the cell survival and can potentially be targeted for therapeutic purposes in DLBCL. In this review, we provide a summary of glycogen and glucose metabolism and discuss their significance in the metabolic reprograming that leads to cell survival and proliferation in DLBCL.
引用
收藏
页码:1028 / 1036
页数:9
相关论文
共 50 条
  • [1] Diffuse large B-cell lymphoma
    Fuchs, David
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2019, 12 (01) : 7 - 11
  • [2] Unraveling the Immune Microenvironment in Diffuse Large B-Cell Lymphoma: Prognostic and Potential Therapeutic Implications
    Koumpis, Epameinondas
    Papoudou-Bai, Alexandra
    Papathanasiou, Konstantina
    Kolettas, Evangelos
    Kanavaros, Panagiotis
    Hatzimichael, Eleftheria
    CURRENT ISSUES IN MOLECULAR BIOLOGY, 2024, 46 (07) : 7048 - 7064
  • [3] Role of microRNA deregulation in the pathogenesis of diffuse large B-cell lymphoma (DLBCL)
    Mazan-Mamczarz, Krystyna
    Gartenhaus, Ronald B.
    LEUKEMIA RESEARCH, 2013, 37 (11) : 1420 - 1428
  • [4] Diffuse Large B-Cell Lymphoma of the Cecum
    Azad, Farhan
    Miranda, Clive Jude
    Ali, Murad
    Ayaz, Muddasir
    ACG CASE REPORTS JOURNAL, 2023, 10 (02)
  • [5] Diffuse large B-cell lymphoma research in Malaysia: A review
    Lim, Kean Ghee
    Sumera, Afshan
    Burud, Ismail Abdul Sattar
    Venkateswaran, Sunil Pazhayanur
    MALAYSIAN JOURNAL OF PATHOLOGY, 2023, 45 (01) : 1 - 10
  • [6] Dasatinib Is Preferentially Active in the Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma
    Cann, Marissa L.
    Herring, Laura E.
    Haar, Lauren L.
    Gilbert, Thomas S. K.
    Goldfarb, Dennis
    Richards, Kristy L.
    Graves, Lee M.
    Lawrence, David S.
    JOURNAL OF PROTEOME RESEARCH, 2019, 18 (01) : 522 - 534
  • [7] Diffuse large B-cell lymphoma
    Barraclough, Allison
    Hawkes, Eliza
    Sehn, Laurie H.
    Smith, Sonali M.
    HEMATOLOGICAL ONCOLOGY, 2024, 42 (06)
  • [8] MicroRNAs in Diffuse Large B-Cell Lymphoma (DLBCL): Biomarkers with Prognostic Potential
    Veryaskina, Yuliya A.
    Titov, Sergei E.
    Kovynev, Igor B.
    Fyodorova, Sofya S.
    Berezina, Olga V.
    Zhurakovskij, Igor P.
    Antonenko, Oksana V.
    Demakov, Sergei A.
    Demenkov, Pavel S.
    Ruzankin, Pavel S.
    Tarasenko, Anton S.
    Pospelova, Tatiana I.
    Zhimulev, Igor F.
    CANCERS, 2025, 17 (08)
  • [9] The Role of microRNA-155 as a Biomarker in Diffuse Large B-Cell Lymphoma
    Koumpis, Epameinondas
    Georgoulis, Vasileios
    Papathanasiou, Konstantina
    Papoudou-Bai, Alexandra
    Kanavaros, Panagiotis
    Kolettas, Evangelos
    Hatzimichael, Eleftheria
    BIOMEDICINES, 2024, 12 (12)
  • [10] Emerging drugs for diffuse large B-cell lymphoma
    Mondello, Patrizia
    Younes, Anas
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (04) : 439 - 451